Cargando…
CpG increases vaccine antigen-specific cell-mediated immunity when administered with hepatitis B vaccine in HIV infection
BACKGROUND: Lack of adequate adjuvancy is a possible explanation for lack of vaccine immunogenecity. Immunostimulatory CpGs are potent vaccine adjuvants and may be an important component of the development vaccines, particularly those for which a cellular immune response is required for protection....
Autores principales: | Angel, Jonathan B, Cooper, Curtis L, Clinch, Jennifer, Young, Charlene D, Chenier, Andreane, Parato, Karl G, Lautru, Michael, Davis, Heather, Cameron, Donald W |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2526993/ https://www.ncbi.nlm.nih.gov/pubmed/18700037 http://dx.doi.org/10.1186/1476-8518-6-4 |
Ejemplares similares
-
CpG Oligonucleotides as Cancer Vaccine Adjuvants
por: Shirota, Hidekazu, et al.
Publicado: (2015) -
Suppressive CpG
por: Van Epps, Heather L.
Publicado: (2005) -
Adjuvant Activity of CpG-Oligonucleotide Administered Transcutaneously in Combination with Vaccination Using a Self-Dissolving Microneedle Patch in Mice
por: Hirobe, Sachiko, et al.
Publicado: (2021) -
Effect of Calcium Carbonate Encapsulation on the Activity of Orally Administered CpG Oligonucleotides
por: Kayraklioglu, Neslihan, et al.
Publicado: (2017) -
Immunostimulatory effects of three classes of CpG oligodeoxynucleotides on PBMC from HCV chronic carriers
por: Cooper, Curtis L, et al.
Publicado: (2008)